$17.78−0.87 (−4.66%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
MiniMed Group (MMED) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
28 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue compounds ~12.1%/yr (FY24→FY26), net margin −10.7%.
The four lines that matter · FY24–FY26
Revenue ($M)▲14.3%
3,102.0
FY24→FY26CAGR +12.1%/yr
Net income ($M)▼56.3%
−333.0
FY24→FY26CAGR —
Free cash flow ($M)▼692.5%
−420.0
FY24→FY26CAGR —
Diluted EPS▼54.8%
−1.30
FY24→FY26CAGR —
What the income statement says · FY24–FY26
Where every revenue dollar goes · FY26 ($M)
-11¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 58.2% → 54.2%. Net margin -10.7% is below the sector median.
The receipt · income statement · FY24–FY26 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY26 | FY25 | FY24 | YoY | CAGR 24→26 |
|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||
Revenue | 3,222.0 | 3,102.0 | 2,715.0 | 2,469.0 | ▲14.3% | +12.1% |
Cost of revenue | 1,486.0 | 1,422.0 | 1,187.0 | 1,032.0 | ▲19.8% | +17.4% |
Gross profit | 1,736.0 | 1,680.0 | 1,528.0 | 1,436.0 | ▲9.9% | +8.2% |
Research & development | 438.0 | 448.0 | 436.0 | 437.0 | ▲2.8% | +1.3% |
Selling, general & admin | 1,212.0 | 1,183.0 | 1,080.0 | 1,057.0 | ▲9.5% | +5.8% |
Total operating expenses | 1,908.0 | 1,870.0 | 1,673.0 | 1,505.0 | ▲11.8% | +11.5% |
Operating incomefeeds ROC rank | −172.0 | −190.0 | −146.0 | −69.0 | ▼30.1% | — |
Other income, net | 0.0 | 1.0 | −1.0 | −1.0 | — | — |
Pretax income | −172.0 | −189.0 | −147.0 | −70.0 | ▼28.6% | — |
Income tax | 129.0 | 128.0 | 52.0 | 38.0 | ▲146.2% | +83.5% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −314.0 | −333.0 | −213.0 | −112.0 | ▼56.3% | — |
| Per share | ||||||
Diluted EPSbuyback-sensitive | −1.22 | −1.30 | −0.84 | −0.44 | ▼54.8% | — |
Diluted shares (mn) | 281.00 | 256.60 | 252.80 | 252.80 | ▲1.5% | +0.7% |
| Margins | ||||||
Gross margin34th pct in Healthcare | 53.9% | 54.2% | 56.3% | 58.2% | ▼2.1pp | −4.0pp |
Operating margin | −5.3% | −6.1% | −5.4% | −2.8% | ▼0.7pp | −3.3pp |
Net margin27th pct in Healthcare | −9.7% | −10.7% | −7.8% | −4.5% | ▼2.9pp | −6.2pp |
† TTM = trailing four quarters through 2026-07-31.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-06-29 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was MiniMed Group's revenue last fiscal year?
MiniMed Group reported revenue of $3,102.0M in fiscal 2026, up 14.3% from fiscal 2025.
What was MiniMed Group's net income?
MiniMed Group reported net income of −$333.0M in fiscal 2026, a net margin of −10.7%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

